# Onward Therapeutics Closes NT$900 Million (approximately US$28 Million) Series B Financing to Advance Clinical-Stage Oncology Pipeline

- Source: PR Newswire M&A
- Published: 2026-11-17T23:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/onward-therapeutics-closes-nt900-million-approximately-us28-million-series-b-financing-to-advance-clinical-stage-oncology-pipeline-302942490.html
- Canonical: https://groundlevelnews.com/story/onward-therapeutics-closes-nt-900-million-approximately-us-28-million--21eee2/

First capital increase since relocating global headquarters to Taiwan; Company targets Emerging Stock Board registration by the end of 2027 TAIPEI and EPALINGES, Switzerland and PARIS, Nov. 17, 2026 /PRNewswire/ -- Onward Therapeutics, Inc. ("Onward Therapeutics" or the "Company") today...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._
